Gilead Sciences, Inc. $GILD Stock Sold by Calamos Advisors LLC

Calamos Advisors LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 10.2% during the 3rd quarter, HoldingsChannel reports. The firm owned 320,159 shares of the biopharmaceutical company’s stock after selling 36,329 shares during the period. Calamos Advisors LLC’s holdings in Gilead Sciences were worth $47,720,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of GILD. PFS Partners LLC raised its holdings in shares of Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 96 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in Gilead Sciences during the 2nd quarter worth about $25,000. Laurel Wealth Advisors LLC bought a new position in Gilead Sciences during the 3rd quarter worth about $29,000. Kimelman & Baird LLC bought a new position in Gilead Sciences during the 2nd quarter worth about $25,000. Finally, Toth Financial Advisory Corp increased its position in Gilead Sciences by 85.5% during the 3rd quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 100 shares during the period. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Down 0.4%

Shares of Gilead Sciences stock traded down $0.68 during trading on Friday, reaching $166.89. The company’s stock had a trading volume of 5,817,414 shares, compared to its average volume of 6,406,722. Gilead Sciences, Inc. has a 1-year low of $116.88 and a 1-year high of $176.58. The company has a market cap of $207.00 billion, a price-to-earnings ratio of -52.81 and a beta of 0.35. The company has a quick ratio of 0.95, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. The company has a 50-day simple moving average of $153.04 and a two-hundred day simple moving average of $140.94.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion during the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. Gilead Sciences’s revenue was up 6.8% on a year-over-year basis. During the same period last year, the firm posted $2.47 EPS. As a group, equities analysts forecast that Gilead Sciences, Inc. will post -1.07 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.0%. Gilead Sciences’s dividend payout ratio is currently -103.80%.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the transaction, the director directly owned 10,066 shares in the company, valued at $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of Gilead Sciences stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $148.62, for a total value of $2,675,160.00. Following the sale, the director directly owned 12,894 shares of the company’s stock, valued at $1,916,306.28. This trade represents a 58.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 239,310 shares of company stock valued at $38,945,617 over the last three months. Company insiders own 0.30% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: New HIV-prevention data showed twice-yearly lenacapavir achieved nearly twice the one-year treatment persistence of daily oral F/TDF, a result that could support Gilead’s long-acting HIV-prevention strategy. Article: New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence
• Positive Sentiment: In the Phase 3 IDEAL study, Livdelzi (seladelpar) achieved ALP normalization in about 75% of participants with primary biliary cholangitis. The results may strengthen its case for broader second-line use, although the stock reportedly fell following the update. Article: Gilead’s Livdelzi Achieves 75% ALP Normalization
• Positive Sentiment: Recent third-quarter results beat analyst estimates for earnings and revenue, and Gilead raised full-year product-sales guidance. The company also maintained its quarterly dividend at $0.82 per share. Article: Did Earnings Beat Just Shift Gilead Sciences’ Investment Narrative?
• Neutral Sentiment: CEO Daniel O’Day sold more than 112,000 shares across November 4–5, but the transactions were conducted under a pre-arranged Rule 10b5-1 plan. He retained 551,683 shares, which may temper concerns about the sales. SEC Form 4 filing

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on GILD shares. Leerink Partners lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Scotiabank increased their price objective on shares of Gilead Sciences from $177.00 to $200.00 and gave the company a “sector outperform” rating in a research note on Friday, October 30th. Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a report on Friday, October 30th. Sanford C. Bernstein reissued an “outperform” rating and issued a $175.00 price objective on shares of Gilead Sciences in a research note on Monday. Finally, Barclays reduced their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 29th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $170.15.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.